ID

16688

Descripción

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Study Drug Administration

Link

https://clinicaltrials.gov/ct2/show/NCT00373425

Palabras clave

Versiones (2)
  1. 27/7/16 27/7/16 -
  2. 1/8/16 1/8/16 -
Subido en

1 de agosto de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425

Inglés

Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 formularios  
Study Drug Administration
Descripción

Study Drug Administration

Start Date
Descripción

Study Drug Administration Start Date

Tipo de datos

date

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0808070
Administered Dose
Descripción

Dose

Tipo de datos

float

Unidades de medida
  • mg
Alias
UMLS CUI [1]
C0178602
mg
Stop Date
Descripción

Study Drug Administration Stop Date

Tipo de datos

date

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0806020
Dose Modification
Descripción

Record toxicities on the Adverse Events page.

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C1707811
UMLS CUI [1,2]
C0392360
If other, specify:
Descripción

Other Dose Modification Reason

Tipo de datos

text

Alias
UMLS CUI [1,1]
C1707811
UMLS CUI [1,2]
C3840932
Missed Doses
Descripción

Record the number of missed doses, if any, for the time between the start and stop dates.

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C1709043
UMLS CUI [1,2]
C0750480
Volver a la parte superior de la página

Similar models

Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Study Drug Administration
Study Drug Administration Start Date
Item
Start Date
date
C0013227 (UMLS CUI [1,1])
C0808070 (UMLS CUI [1,2])
Dose
Item
Administered Dose
float
C0178602 (UMLS CUI [1])
Study Drug Administration Stop Date
Item
Stop Date
date
C0013227 (UMLS CUI [1,1])
C0806020 (UMLS CUI [1,2])
Item
Dose Modification
integer
C1707811 (UMLS CUI [1,1])
C0392360 (UMLS CUI [1,2])
Study Drug Dose Modification
Code List
Dose Modification
CL Item
Drug-related Toxicity (AE) (1)
CL Item
Nondrug-related Toxicity (AE) (2)
CL Item
Patient Request  (3)
CL Item
Toxicity lmproved  (4)
CL Item
No Modification (5)
CL Item
Other (specify) (6)
Other Dose Modification Reason
Item
If other, specify:
text
C1707811 (UMLS CUI [1,1])
C3840932 (UMLS CUI [1,2])
Missed Doses
Item
Missed Doses
integer
C1709043 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial